Angelman Syndrome
Angelman Syndrome Market

Angelman Syndrome (AS) is a complex genetic disorder, which primarily affects the nervous system. The characteristic features of this disease include delayed development, intellectual disability, severe speech impairment, and problems with movement and balance (ataxia).

 

Angelman Syndrome Epidemiological Segmentation 

The Epidemiological Segmentation of Angelman Syndrome in 7MM from 2017 to 2030 is segmented as:- 

  • Total Prevalent cases of Angelman Syndrome
  • Diagnosed Prevalent Cases of Angelman Syndrome
  • Angelman Syndrome Cases by Mutation Types
  • Angelman Syndrome associated with Clinical Manifestations

 

Angelman Syndrome Epidemiology 

  • Total prevalent cases of Angelman Syndrome in 7 MM in 2017 was 57,716  
  • The prevalence of Angelman Syndrome in the United States in 2017 was 21,715  
  • The prevalence of Angelman Syndrome in Germany was 6,448 in 2017 

 

Angelman Syndrome Market

The therapeutic market of Angelman Syndrome in 7MM in 2017 was USD 255 Million.  

 

Angelman Syndrome Market Drivers 

  • Biomarker Studies
  • Increasing Prevalence of Angelman Syndrome
  • Molecular Level Diagnosis

 

Angelman Syndrome Market Barriers

  • Lack of awareness
  • Lack of late-stage clinical trials
  • Lack of Data
  • Economic Burden


Angelman Syndrome Emerging Drugs

Angelman Syndrome Emerging Drugs are Gaboxadol, GTX-101, GT-AS/AGIL-AS, and many others. 

 

Angelman Syndrome Key Players

Angelman Syndrome key players are Ovid Therapeutics, GeneTx Biotherapeutics, PTC Therapeutics, and many others.